Compare AHMA & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHMA | ARMP |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.1M | 296.7M |
| IPO Year | N/A | 1996 |
| Metric | AHMA | ARMP |
|---|---|---|
| Price | $5.85 | $11.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 34.5K | ★ 45.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $180.72 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.25 | $0.90 |
| 52 Week High | $39.50 | $13.75 |
| Indicator | AHMA | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 35.95 | 64.18 |
| Support Level | $5.70 | $5.14 |
| Resistance Level | $9.75 | $12.23 |
| Average True Range (ATR) | 0.54 | 1.06 |
| MACD | 0.24 | 0.04 |
| Stochastic Oscillator | 10.15 | 82.58 |
Ambitions Enterprise Management Co LLC, through its subsidiaries in the UAE, operates as a tour operator, travel agency, and event planning and management services provider. It provides two lines of services, namely, MICE management, a comprehensive coordination and organization of events, and one-stop tourism, a comprehensive travel product that is designed to provide tourists with all the necessary components of a trip in a single and convenient package, which typically include transportation, accommodations, meals, and guided tours or activities.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.